Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib plus Alpelisib in metastatic breast cancer (ComboMATCH)
NCT05967286Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Oct 2023
- Primary completion
- Apr 2025
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of alpelisib in breast cancer, sponsored by National Cancer Institute. Planned start Oct 2023; status: withdrawn.
02
Drugs
alpelisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05967286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05967286.